EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeitOpen Access

Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis

Meghna Joseph, Mrinal Murali Krishna, Vanessa Karlinski Vizentin, Henrique Provinciatto, Chidubem Ezenna

Neonatology · 2025

DOI: 10.1159/000547537 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neonatology, 2025. Verfasst von Meghna Joseph und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Medical College Thiruvananthapuram, Thiruvananthapuram, India. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Azithromycin, Anti-Bacterial Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Azithromycin, with its antimicrobial and anti-inflammatory properties, has been explored as a potential option for preventing bronchopulmonary dysplasia (BPD) in preterm infants.

Objective

We performed a meta-analysis of randomized controlled trials (RCTs) comparing azithromycin with placebo for the prevention of BPD in preterm infants.

Methods

PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central databases were searched for studies comparing azithromycin versus placebo in preterm infants. Outcomes of interest included the composite of BPD and death, BPD, death, grade 2 or higher necrotizing enterocolitis (NEC), grade 3 or 4 intraventricular hemorrhage (IVH), retinopathy of prematurity (RoP), duration of mechanical ventilation, and postnatal corticosteroid requirement. Random-effects model was used to generate risk ratio (RR), mean difference (MD), and 95% confidence interval (CI) (CRD42024558752).

Results

The meta-analysis included 6 RCTs including 1,360 infants (azithromycin n = 680, 50%). The composite of BPD or death (RR: 0.95; 95% CI: 0.83–1.10; p = 0.53; I2 = 50.2%), BPD (RR: 0.98; 95% CI: 0.83–1.15; p = 0.77; I2 = 38.1%), death (RR: 0.88; 95% CI: 0.66–1.19; p = 0.41; I2 = 0%), NEC (RR: 0.94; 95% CI: 0.69–1.26; p = 0.67; I2 = 0%), IVH (RR: 1.22; 95% CI: 0.89–1.68; p = 0.22; I2 = 3.5%), RoP (RR: 1.35; 95% CI: 0.43–4.28; p = 0.61; I2 = 76.3%), duration of mechanical ventilation (MD: 0.13; 95% CI: −1.35 to 1.60; p = 0.87; I2 = 0%), and postnatal corticosteroid requirement (RR: 0.84; 95% CI: 0.64–1.08; p = 0.18; I2 = 34.5%) were similar between the groups.

Conclusion

In preterm infants, azithromycin did not significantly change the risk of adverse clinical outcomes compared with placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchopulmonary DysplasiaAzithromycinAnti-Bacterial AgentsHumansInfant, NewbornInfant, PrematureRandomized Controlled Trials as TopicRespiration, ArtificialEnterocolitis, NecrotizingRetinopathy of PrematurityTreatment OutcomeCerebral Intraventricular Hemorrhage

Stichwörter der Autor:innen

AzithromycinBronchopulmonary dysplasiaPreterm infants

Substanzen

AzithromycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Medicine, Medical College Thiruvananthapuram, Thiruvananthapuram, India.
  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Departament of Medicine, Barão de Mauá University Center, Ribeirão Preto, São Paulo, Brazil.
  • Department of Medicine, University of Massachusetts - Baystate Medical Center, Springfield, Massachusetts, USA, cezenna349@gmail.com.

Zitieren

APA

Joseph, M., Murali Krishna, M., Karlinski Vizentin, V., Provinciatto, H., & Ezenna, C. (2025). Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis. Neonatology. https://doi.org/10.1159/000547537

Vancouver

Joseph M, Murali Krishna M, Karlinski Vizentin V, Provinciatto H, Ezenna C. Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis. Neonatology. 2025. doi:10.1159/000547537

BibTeX
@article{Joseph2025,
  author = {Joseph, Meghna and Murali Krishna, Mrinal and Karlinski Vizentin, Vanessa and Provinciatto, Henrique and Ezenna, Chidubem},
  title = {Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis},
  journal = {Neonatology},
  year = {2025},
  doi = {10.1159/000547537}
}
Kostenlos starten →